An antiaggregant, used for the prevention of thrombotic complications in patients with acute coronary syndrome (ACS), who are planned to undergo percutaneous coronary angioplasty and for prevention of stent thrombosis in acute coronary syndromes. The medicine is a receptor antagonist of P2Y12class to adenosine diphosphate (ADP), and consequently inhibits the activation and aggregation of platelets. Since platelets are involved in the development of atherosclerosis complications, the inhibition of platelet function may lead to a decrease in the frequency of cardiovascular complications.
Prasugrel product description
Refers to the clinical and pharmacological group of antiplatelet agents. This medication is a P2Y12 receptor antagonist to adenosine diphosphate. The effect of the drug is inhibition of activation and aggregation of platelets. Platelets take an active part in the development of the complication of atherosclerosis, platelet inhibition processes can lead to a significant reduction in the incidence of complications in the cardiovascular system of the patient. The process of drug exposure begins after 1-hour from the time of taking Prasugrel. Approximately 90% of patients within 1-hour show inhibition of platelet aggregation functions in 50% size. When taking the medication inward, Prasugrel is rapidly absorbed. Absorption processes are not dependent on eating, so the use of the medication is not limited to the mode of eating. The maximum concentration of the active substance in the blood serum of the patient is reached after 30 minutes from the time of taking the drug. The appointment and determination of dosages, as well as the duration of the course of treatment, should be performed by the treating healthcare specialist who knows the patient's medical history and can anticipate possible allergic reactions of the patient's organism to a particular stimulus in advance. Indications for the appointment of this medication can be a prevention of thrombotic complications in patients with an acute coronary syndrome, also for those who are scheduled to undergo percutaneous coronary angioplasty. This medical preparation can be prescribed for: unstable angina, myocardial infarction, as well as patients who will be assigned primary delayed percutaneous coronary angioplasty.
Prasugrel safety information
The medical care with Prasugrel begins with oral administration by the patient of a loading dosage equal to 60 mg, after which the drug is taken in a maintenance dosage of 10 mg once a day.
To prevent unwanted reactions, patients receiving Prasugrel in therapeutic muds should take acetylsalicylic acid from 75 to 325 mg.
The use of Prasugrel is not recommended in case you have some of the following contraindications : the condition of an increased risk of bleeding; a stroke in the anamnesis; impaired cerebral circulation; hepatic insufficiency of severe form; hypersensitivity to the active substance; deficiency of lactase in the patient's body; children and adolescents under 18; lactose intolerance; glucose-galactose malabsorption syndrome. The overdose of Prasugrel may lead to an increase in bleeding time and subsequent complications.
Prasugrel side effects
In order to avoid side effects and achieve maximum effectiveness from the treatment with Prasugrel, it is necessary to adhere to the dosage and the course of treatment prescribed by the healthcare specialist strictly. The following side effects may develop in patients: bleeding is possible; rectal bleeding; gastrointestinal bleeding; bleeding from the gums; bloody stools; hematoma at the site of the vascular puncture; rash; anemia; hemorrhage in the eye.